MedTrace Logo

Probiotics for Liver Cirrhosis With Portal Hypertension

NCT01598064 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2014-09-18

Study results available
· View outcomes & findings →

Summary

Recent studies indicate that probiotics can stimulate intestinal immunity and tighten the junctions of epithelial cells. By these ways, probiotics can reduce bacterial translocation; hence, they can ameliorate systemic inflammatory status. Because cirrhotic patients with portal hypertension often suffer from infections from intestinal flora, the investigators speculate that probiotics will be beneficial to those patients.

Conditions

Interventions

DIETARY_SUPPLEMENT

GK#10

GK#10, 1 pack tid

DRUG

Placebo

Placebo 1 pack tid po

Sponsors & Collaborators

  • Grape King Bio Ltd.

    collaborator INDUSTRY

  • Po-Lin Chen, MD

    lead OTHER

Principal Investigators

  • Xi-Zhang Lin · Professor

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01598064 on ClinicalTrials.gov